NEW YORK, Feb. 2, 2018 /PRNewswire/ — WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AKRX, COLL, HZNP, and IRWD which can be accessed for free by signing up to www.wallstequities.com/registration. Patent expiration of branded drugs is one of the key influencers for the growth and prime reason for generating more revenue for the Generic Drugs market. Moreover, new emerging markets of developing countries and low cost of generic drugs are majorly responsible for thickening the growth of this market. Today, WallStEquities.com assesses Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), Horizon Pharma PLC (NASDAQ: HZNP), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Thursday, shares in Lake Forest, Illinois headquartered Akorn Inc. recorded a trading volume of 1.09 million shares. The stock ended at $32.57, up 1.09% from the last trading session. The Company’s shares have surged 67.46% over the past year. The stock is trading slightly below its 50-day moving average by 0.22%. Furthermore, shares of Akorn have a Relative Strength Index (RSI) of 46.00. Get the full research report on AKRX for free by clicking below at:
Canton, Massachusetts headquartered Collegium Pharmaceutical Inc.’s stock finished yesterday’s session 0.80% lower at $23.65 with a total trading volume of 455,202 shares. The Company’s shares have gained 26.47% in the last month, 128.94% over the previous three months, and 39.20% over the past year. The stock is trading above its 50-day and 200-day moving averages by 23.00% and 83.94%, respectively. Furthermore, shares of Collegium Pharma, which develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases, have an RSI of 62.14.
On January 10th, 2018, Collegium Pharma announced that it has closed the transactions contemplated by its commercialization agreement with Depomed, Inc., pursuant to which the former has the right to commercialize Nucynta® (tapentadol) Immediate Release and Nucynta® ER (tapentadol) Extended Release tablets in the US. The free technical report on COLL can be accessed at:
At the close of trading on Thursday, shares in Dublin, Ireland headquartered Horizon Pharma PLC rose 1.03%, ending the day at $14.70. The stock recorded a trading volume of 1.31 million shares. The Company’s shares have advanced 8.41% in the previous three months. The stock is trading 11.31% above its 200-day moving average. Moreover, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the US and internationally, have an RSI of 44.10.
On January 12th, 2018, research firm Mizuho upgraded the Company’s stock rating from ‘Neutral’ to ‘Buy’ while revising its previous target price from $12 a share to $18 a share.
On January 29th, 2018, Horizon Pharma announced that its Q4 and full-year 2017 financial results will be released on February 28th, 2018. Following the announcement, Management will host a live webcast at 8:00 a.m. ET to review the results. The live webcast and replay can be accessed on the Company’s investor website. Sign up for free on Wall St. Equities and claim the latest report on HZNP at:
Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.’s shares ended the day 5.60% lower at $13.98 with a total trading volume of 1.50 million shares. The stock is trading 9.96% below its 50-day moving average. Shares of the Company, which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 37.08.
On January 05th, 2018, research firm Bank of America/ Merrill downgraded the Company’s stock rating from ‘Buy’ to ‘Underperform’.
On January 16th, 2018, Ironwood Pharma and Allergan PLC (together, “the Companies”) announced that they have reached an agreement with wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd. (“Sun Pharma,” including its subsidiaries and/or associate companies), resolving patent litigation brought in response to the latter’s abbreviated new drug application seeking approval to market a generic version of LINZESS (linaclotide) prior to the expiration of the Companies’ applicable patents. As a result of the settlement, all Hatch-Waxman litigation between the Companies and Sun Pharma regarding LINZESS patents will be dismissed. See the free research coverage on IRWD at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities